(CLPT) Clearpoint Neuro - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US18507C1036
CLPT: Electrodes, Biopsy Needles, Laser Catheters, Pharmaceuticals
ClearPoint Neuro, Inc. (NASDAQ:CLPT) is a leading medical device company specializing in minimally invasive surgical solutions for brain interventions. Headquartered in Solana Beach, California, the company was founded in 1998 and rebranded from MRI Interventions, Inc. in February 2020. ClearPoint Neuro is renowned for its innovative ClearPoint system, which integrates advanced MRI-guided technologies to enable precise insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as targeted pharmaceutical infusion into the brain. This system enhances surgical accuracy and minimizes tissue damage, making it a preferred choice for neurosurgeons.
The company has established strategic collaborations with key industry players, including Clinical Laserthermia Systems AB, Koninklijke Philips N.V., UCB Biopharma SRL, the University of California, San Francisco, and NE Scientific, LLC. These partnerships underscore ClearPoint Neuros commitment to advancing neurosurgical techniques and expanding its technological capabilities. The companys focus on improving patient outcomes through cutting-edge, minimally invasive procedures positions it as a pioneer in the neurosurgery device market.
From a technical standpoint, CLPTs stock is currently trading at $14.21 with a 20-day average volume of 222,790 shares. The stock is below its 20-day SMA of $17.61 and 50-day SMA of $16.62, suggesting bearish momentum. However, the 200-day SMA of $11.41 indicates a longer-term upward trend. The Average True Range (ATR) of 1.05 reflects moderate volatility, offering potential trading opportunities.
Fundamentally, ClearPoint Neuro has a market capitalization of $461.22 million, with a price-to-book ratio of 16.60 and a price-to-sales ratio of 15.16, indicating a premium valuation. The negative return on equity (-62.57%) highlights ongoing operational losses, which are common in high-growth, R&D-intensive industries. The absence of a P/E ratio reflects the companys current focus on reinvestment over profitability.
3-Month Forecast: Based on the provided data, CLPTs stock is expected to face short-term headwinds due to its position below key moving averages. The 20-day and 50-day SMAs at $17.61 and $16.62, respectively, may act as resistance levels. However, the longer-term 200-day SMA at $11.41 suggests underlying strength. The ATR of 1.05 indicates manageable volatility, potentially offering entry points for traders. The high P/B and P/S ratios signal investor confidence in future growth, despite current losses. Overall, the stock may consolidate in the near term but could rebound if it breaks above the 50-day SMA.
Additional Sources for CLPT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CLPT Stock Overview
| Market Cap in USD | 361m |
| Sector | Healthcare |
| Industry | Medical Devices |
| GiC Sub-Industry | Health Care Equipment |
| IPO / Inception | 2020-02-12 |
CLPT Stock Ratings
| Growth 5y | 51.4% |
| Fundamental | -9.49% |
| Dividend | 0.0% |
| Rel. Strength Industry | 75.6 |
| Analysts | 5/5 |
| Fair Price Momentum | 11.56 USD |
| Fair Price DCF | - |
CLPT Dividends
No Dividends PaidCLPT Growth Ratios
| Growth Correlation 3m | -7.9% |
| Growth Correlation 12m | 88.8% |
| Growth Correlation 5y | -0.9% |
| CAGR 5y | 25.75% |
| CAGR/Max DD 5y | 0.30 |
| Sharpe Ratio 12m | -1.16 |
| Alpha | 62.76 |
| Beta | 2.03 |
| Volatility | 76.10% |
| Current Volume | 200.6k |
| Average Volume 20d | 259.4k |
As of March 14, 2025, the stock is trading at USD 12.56 with a total of 200,632 shares traded.
Over the past week, the price has changed by -4.78%, over one month by -31.66%, over three months by -18.04% and over the past year by +75.17%.
Neither. Based on ValueRay Fundamental Analyses, Clearpoint Neuro is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -9.49 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CLPT as of March 2025 is 11.56. This means that CLPT is currently overvalued and has a potential downside of -7.96%.
Clearpoint Neuro has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy CLPT.
- Strong Buy: 3
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CLPT Clearpoint Neuro will be worth about 13.7 in March 2026. The stock is currently trading at 12.56. This means that the stock has a potential upside of +8.68%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 23 | 83.1% |
| Analysts Target Price | 17 | 35.4% |
| ValueRay Target Price | 13.7 | 8.7% |